In a randomized prospective clinical trial, treatment of patients with non-cirrhotic NASH using the semi-synthetic FXR agonist, obeticholic acid, demonstrated significant improvement in fibrosis, steatosis, hepatocellular ballooning, and lobular inflammation compared to placebo [47]. This evidence concerns the gene NR1H4 and steatosis.